retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Delivers 22.6% Weight Loss in TRIUMPH-2 and TRIUMPH-3 Trials | Kh Mahfuz Ullah posted on the topic Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Only the back of the upper arm, abdomen, and thigh are approved sites according to MHRA product information

Here are the three main reasons: GLP-1s Help With Conditions That Disproportionately Affect Bipolar Disorder Theres a high percentage of people living with bipolar disorder who also experience metabolic changes in their body that put them at risk for things like heart disease and type 2 diabetes, says Vijay Gorrepati, MD, psychiatrist at UT Health Austins Bipolar Disorder Center in Texas, which is associated with Dell Medical School

Ingredients: Glutathione: A powerful antioxidant that lightens the skin and reduces pigmentation

Lancet 352 , 11721177 (1998)

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss